Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
Barbe R, Belkouchi Y, Menu Y, Cohen R, David C, Kind M, Harguem S, Dawi L, Hadchiti J, Selhane F, Billet N, Ammari S, Bertin A, Lawrance L, Cervantes B, Hollebecque A, Balleyguier C, Cournede PH, Talbot H, Lassau N, Andre T. Barbe R, et al. Among authors: ammari s. Eur J Cancer. 2024 May;202:114020. doi: 10.1016/j.ejca.2024.114020. Epub 2024 Mar 16. Eur J Cancer. 2024. PMID: 38502988
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.
Dercle L, Ammari S, Champiat S, Massard C, Ferté C, Taihi L, Seban RD, Aspeslagh S, Mahjoubi L, Kamsu-Kom N, Robert C, Marabelle A, Schlumberger M, Soria JC, Postel-Vinay S. Dercle L, et al. Among authors: ammari s. Eur J Cancer. 2016 Sep;65:33-42. doi: 10.1016/j.ejca.2016.05.031. Epub 2016 Jul 21. Eur J Cancer. 2016. PMID: 27451022 Clinical Trial.
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferté C. Sun R, et al. Among authors: ammari s. Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18. Eur J Cancer. 2017. PMID: 28826073
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J, Verlingue L, Broutin S, Legoupil C, Touat M, Doucet L, Ammari S, Lacroix L, Ducreux M, Scoazec JY, Malka D, Paci A, Hollebecque A. Delahousse J, et al. Among authors: ammari s. Eur J Cancer. 2018 Feb;90:83-91. doi: 10.1016/j.ejca.2017.11.024. Epub 2018 Jan 4. Eur J Cancer. 2018. PMID: 29274619
Can we trust the calculation of texture indices of CT images? A phantom study.
Caramella C, Allorant A, Orlhac F, Bidault F, Asselain B, Ammari S, Jaranowski P, Moussier A, Balleyguier C, Lassau N, Pitre-Champagnat S. Caramella C, et al. Among authors: ammari s. Med Phys. 2018 Apr;45(4):1529-1536. doi: 10.1002/mp.12809. Epub 2018 Mar 13. Med Phys. 2018. PMID: 29443389
141 results